A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EPL / eplerenone

[Related PubMed/MEDLINE]
Total Number of Papers: 39
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EPL  (>> Co-occurring Abbreviation)
Long Form:   eplerenone
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Eplerenone Ameliorates Cell Pyroptosis in Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction. MR, NLRP3, UUO
2019 Formulation and Characterization of Eplerenone Nanoemulsion Liquisolids, An Oral Delivery System with Higher Release Rate and Improved Bioavailability. BCS, EPL-NEs, PDI
2019 Remodeling of myocardial energy and metabolic homeostasis in a sheep model of persistent atrial fibrillation. AAs, AF, FA, PA, PC, PG, SP, TCA
2018 Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy. GFR, PA
2018 Mineralocorticoid Antagonist Improves Glucocorticoid Receptor Signaling and Dexamethasone Analgesia in an Animal Model of Low Back Pain. DEX, DRG, GR, MR
2018 Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-kappaB and AP-1 signalling. MR, PAECs, RNAPII, SPL, XPB
2017 Eplerenone Prevents Atrial Fibrosis via the TGF-beta Signaling Pathway. ---
2017 Eplerenone Reduces Atrial Fibrillation Burden Without Preventing AtrialElectrical Remodeling. AF, SP
2017 Eplerenone-Resistant Salt-Sensitive Hypertension in Nedd4-2 C2 KO Mice. ASDN, ENaC, KO
10  2017 Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats. EPR, EPRs, HR, MAP, MRs, NC, SHRs, SPIR
11  2016 Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. BP, HOMA-IR, MR, PA, PAC, PRA, SPL, UAE
13  2016 Eplerenone inhibits atrial fibrosis in mutant TGF-beta1 transgenic mice. CTGF, MR
14  2016 Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. ALDO, CKD, IL, MR, ROS
15  2016 Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. BNP, FIN, LV, MR, TAC, VEH
16  2015 Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury. Ang II, Cav-1, L-NAME, MR, NO, WT
17  2015 DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats. CA, MR, SPI
18  2015 Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. AAs, EF, POAF, SPL
19  2015 Eplerenone reduces arterial thrombosis in diabetic rats. AMI, STZ
20  2015 Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity. Ccr, Col I, CsA, CTGF, PAI-1, TGF-beta1, TIF
21  2014 Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice. Ang II, LSD, ND
22  2013 Aldosterone induces electrical remodeling independent of hypertension. ALD, SPI
23  2013 The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BP
24  2012 Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase. ALDO, APC, COX, COX-2
25  2012 Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. SHR, STZ, TGF-beta1
26  2012 Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. MR, ND, SPL
27  2011 Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. ALD, AML, ARR, CR, PA, TEL, UAER
28  2011 Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. AF, DS, HS, MR
29  2011 SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. MR, SPI
30  2011 Study of the mechanisms of aldosterone prothrombotic effect in rats. ALDO, BT, MDA, MR, NO, NOS, SOD
31  2009 Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. 11beta-HSD, GCs, GR and MR, OPG
32  2008 Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. BP, CsA, GFR, MR, RBF
33  2007 Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. alpha-ENaC, AR, SBP
34  2007 Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Ang, MR, TEM
35  2007 Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. ACEI, DSHF, MnSOD, NADPH, SOD, TGF
36  2006 Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. ALDO, MCSA, SBP
37  2006 The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. CON, DOC, DOC8, GR, MR
38  2005 Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. AAC, LV
39  2002 Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. ALDO, MCSA, SD